Alpha Cognition (ACOG) investor relations material

Executive summary

• Q3 was the strongest quarter since ZUNVEYL’s launch, with net product revenue up ~30% QoQ; management reiterated its 2027 operating profitability target.

• Commercial adoption and utilization increased, while real-world evidence highlighted therapeutic-dose attainment and reduced polypharmacy.

Financial highlights

• Q3 net product revenue was $7.75M, versus $6.0M in Q2 and $2.3M in Q3 2025; growth was primarily volume-driven.

• Gross product margin was 94%; operating expenses were $13.7M and operating loss was $6.43M, versus $7.1M in Q2.

• Net loss was $7.62M, or $0.35 per share, versus $8.2M, or $0.38 per share, in Q2.

• Nine-month revenue was $17.40M and net loss was $21.80M; nine-month operating cash use was $23.50M.

• Q3 R&D expense was $1.34M and SG&A was $12.38M, reflecting commercial staffing, marketing, regulatory and stock-based compensation costs.

Outlook and guidance

• FY2026 operating expense guidance remained $50M–$54M; management continued to target operating profitability in 2027.

• Management expects ZUNVEYL revenue to continue growing; current cash is expected to fund planned base operations and commercialization for at least 12 months.

• Costs are expected to rise with commercialization, clinical and preclinical work, manufacturing, hiring and commercial expansion.

• No formulary wins were expected before year-end 2026; broader payer access is viewed as a potential growth driver.